← PROCEPT BioRobotics Corp
| Annual Trend | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|
| Net loss | ($53.0m) | ($59.9m) | ($87.2m) | ($105.9m) | ($91.4m) | ($95.6m) | — | |
| Depreciation and amortization | $2.9m | $3.3m | $2.8m | $3.8m | $5.2m | $6.4m | $7.1m | |
| Stock-based compensation expense | $2.2m | $3.8m | $10.3m | $19.1m | $31.8m | $47.6m | $52.9m | |
| Accounts receivable, net | ($511k) | ($2.9m) | ($10.8m) | ($33.1m) | ($36.0m) | ($898k) | ($27.1m) | |
| Inventory write-down | $109k | $650k | $62k | $995k | $1.9m | $565k | — | |
| Inventory | ($3.1m) | ($6.1m) | ($15.3m) | ($9.8m) | ($17.2m) | ($14.5m) | ($10.3m) | |
| Accounts payable | ($205k) | $812k | $4.0m | $5.8m | ($2.2m) | $6.6m | $3.8m | |
| Property and equipment included in accounts payable and accrued expenses | $210k | $210k | $3.5m | $1.9m | $348k | $969k | — | |
| Accrued compensation | $2.3m | $1.8m | $7.0m | $3.4m | $4.7m | $1.6m | — | |
| Accrued interest expense | $1.0m | $1.0m | $757k | $125k | $134k | $142k | — | |
| Deferred revenue | $127k | $792k | $1.8m | $3.3m | $3.7m | $3.3m | — | |
| Prepaid expenses and other current assets | ($339k) | ($2.6m) | ($1.9m) | $1.1m | ($3.2m) | ($1.1m) | — | |
| Other assets | — | $0 | ($51k) | ($868k) | ($1.6m) | ($2.9m) | — | |
| Other liabilities | $199k | $2.5m | $2.7m | ($1.1m) | $1.8m | $1.9m | — | |
| Net cash used in operating activities | ($48.3m) |
($57.3m)
-18.60%
|
($80.4m)
-40.20%
|
($108.0m)
-34.36%
|
($99.2m)
+8.14%
|
($49.0m)
+50.63%
|
($74.3m)
-51.76%
|
|
| Purchases of property and equipment | ($233k) | ($592k) | ($2.7m) | ($25.2m) | ($4.4m) | ($9.4m) | ($10.6m) | |
| Net cash used in investing activities | ($233k) | ($592k) | ($2.7m) | ($25.2m) | ($4.4m) | ($9.4m) | ($10.6m) | |
| Proceeds from issuance of common stock under employee stock purchase plan | — | $0 | $2.4m | $3.6m | $4.5m | $6.4m | $0 | |
| Proceeds from issuance of common stock from the exercise of stock options, net | $2.3m | $4.2m | $4.0m | $2.5m | $11.1m | $4.8m | $0 | |
| Proceeds from issuance of common stock, net of issuance costs | — | $0 | $2.4m | $161.7m | $164.5m | $0 | $0 | |
| Net cash provided by financing activities | $106.8m |
$262.1m
+145.49%
|
$3.6m
-98.62%
|
$167.8m
+4545.49%
|
$180.1m
+7.35%
|
$11.2m
-93.79%
|
$10.2m
-8.56%
|
|
| Net increase (decrease) in cash, cash equivalents and restricted cash | $58.2m | $204.2m | ($79.4m) | $34.6m | $76.5m | ($47.2m) | — | |
| Effect of exchange rates on cash, cash equivalents and restricted cash | — | — | — | $0 | $0 | ($74k) | — | |
| Restricted cash | $777k | $777k | $3.8m | $3.0m | $3.0m | $3.0m | — | |
| Additional Supplementary Disclosures | ||||||||
| Additional Supplementary Disclosures | ||||||||
| Change in fair value in derivative liability | — | — | $283k | $107k | $114k | $0 | — | |
| Non-cash lease adjustment | ($157k) | ($345k) | $1.5m | $13k | ($383k) | ($508k) | — | |
| Provision for credit losses | — | — | $0 | $0 | $840k | $219k | — | |
| (Gain) loss on foreign currency transactions | — | $0 | $3.3m | $0 | $0 | $157k | — | |
| Loan facility liability | — | — | — | $0 | $0 | ($2.0m) | — | |
| Reimbursements for leasehold improvements from operating leases | — | $0 | $327k | $5.0m | $2.6m | $0 | — | |
| Beginning of the period | $100.9m | $305.1m | $225.7m | $260.3m | $336.8m | $289.5m | — | |
| Cash and cash equivalents | $100.1m | $304.3m | $221.9m | $257.2m | $333.7m | $286.5m | $305.8m | |
| Interest paid | $4.0m | $4.8m | $4.3m | $4.1m | $4.0m | $3.5m | $3.3m |